Key clinical point: A newly developed mRNA-based liquid biopsy is likely to have clinical utility in the diagnosis and monitoring management of prostate cancer, with accuracy significantly higher than the prostate-specific antigen (PSA) test.

Major finding: The diagnostic accuracy of the test was 92.4%; sensitivity and specificity were 94.4% and 89.7%, respectively. The detection rate was 96% during biochemical recurrence. PSA test accuracy (greater than 10 ng/mL) in prostate cancer diagnosis was 48% (P less than.0001).

Study details: Assessment of a liquid biopsy assay based on a circulating-free mRNA (27-gene) prostate cancer signature identified using transcriptomic analysis.

Disclosures: The research was funded by Wren Laboratories. Ignat Drozdov, Alexandra Kitz, and Irvin Modlin reported ties with Wren Laboratories. The remaining authors declared no conflicts of interest.